A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Inclusion Criteria:
Have been diagnosed with type 2 diabetes mellitus (T2DM)
Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
Have HbA1c at screening
Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
Have increased risk for cardiovascular (CV) events due to:
Are of stable weight (± 5%) for at least 90 days prior to screening
Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening
Exclusion Criteria:
Sun City West, Arizona 85375, United States
Troy, Michigan 48098, United States
Pittsburgh, Pennsylvania 15243, United States
Norfolk, Virginia 23510, United States
CABA, C1015ABO, Argentina
Acaraju, 49055-530, Brazil
Pardubice V, 530 02, Czechia
Praha 9 - Klanovice, 190 14, Czechia
Pohlheim, 35415, Germany
Roma, 00168, Italy
Trieste, 34125, Italy
Culiacán, 80230, Mexico
Pamukkale, 20070, Turkey (Türkiye)